# EDGAR Filing Document

**Accession Number:** 0001293818
**File Stem:** 0001829126-25-010286
**Filing Date:** 2025-12
**Character Count:** 9722
**Document Hash:** 286d3faa8af02571cb4b3f0728758142
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-25-010286.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001829126-25-010286

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251217

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OPGEN INC
- **CENTRAL INDEX KEY:** 0001293818
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 061614015
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37367
- **FILM NUMBER:** 251601633

**BUSINESS ADDRESS:**
- **STREET 1:** 9717 KEY WEST AVENUE
- **STREET 2:** SUITE 100
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 301-869-9683

**MAIL ADDRESS:**
- **STREET 1:** 9717 KEY WEST AVENUE
- **STREET 2:** SUITE 100
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

?xml version='1.0' encoding='ASCII'?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**December 17, 2025 Date of Report (date of earliest event reported)**

**OPGEN, INC.**

**(Exact name of Registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37367** | **06-1614015** |
| **(State or other jurisdiction of <br> incorporation or organization)** | **(Commission<br> File Number)** | **(I.R.S. Employer <br> Identification Number)** |

---

**23219 Stringtown Road, Suite 300 Clarksburg, MD 20871 (Address of principal executive offices)(Zip code)**

**(240) 813-1260 (Registrant's telephone number, including area code)**

**Not Applicable (Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | OPGN | OTC Markets Group, Inc. |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.** |

---

As previously reported, on August 22, 2024, OpGen, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with AEI Capital Ltd. (the "Purchaser"), pursuant to which the Company had the right, in its discretion, to sell to the Purchaser, at any time prior to September 30, 2024, shares of common stock, par value $0.01 per share (the "Shares"), of the Company having an aggregate value of up to $3.0 million (the "Financing"). On October 3, 2024, the Company and the Purchaser entered into a First Amendment to the Purchase Agreement (the "First Amendment"). The First Amendment amended the Purchase Agreement by: (1) granting the Company the right to sell two additional tranches of common stock to the Purchaser of $3.0 million each, for an aggregate amount of $9.0 million under the Purchase Agreement; and (2) extending the Company's ability to sell shares of common stock to the Purchaser under the Purchase Agreement until December 31, 2025. On December 17, 2025, the Company and the Purchaser entered into a Supplemental Letter to the Purchase Agreement (the "Supplemental Letter"), which amended the Purchase Agreement by extending the Company's ability to sell shares of common stock to the Purchaser until December 31, 2026.

The foregoing description of the Supplemental Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Supplemental Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 3.02** | **Unregistered Sales of Equity Securities.** |

---

The disclosure required by this Item and included in Item 1.01 of this Current Report is incorporated herein by reference. The shares of common stock of the Company that may be sold under the Purchase Agreement, as amended, will be sold without registration under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and Regulations D and S promulgated thereunder as sales to accredited investors and in reliance on similar exemptions under applicable state laws.

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On December 18, 2025, David Lazar notified the Company of his resignation as President of the Company effective as of January 8, 2026. Mr. Lazar's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 10.1 | [Supplemental Letter, dated December 17, 2025, by and between AEI Capital Ltd. and OpGen, Inc. relating to Securities Purchase Agreement, dated August 22, 2024, and First Amendment thereto, dated October 3, 2024.](opgeninc_ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: December 23, 2025 | **OpGen, Inc.** | **OpGen, Inc.** | **OpGen, Inc.** |
|  | By: | /s/ Christian-Laurent Benoit Bonte | /s/ Christian-Laurent Benoit Bonte |
|  |  | Name: | Christian-Laurent Benoit Bonte |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**OpGen, Inc.**

23219 Stringtown Road, Suite 300

Clarksburg, MD 20871 USA.

(hereinafter to be referred to as "**Company**")

**Date: 17th December 2025**

**AEI Capital Ltd.** (Registration No. 970490-V)

Intershore Chambers, Road Town,

Tortola, British Virgin Islands

(hereinafter to be referred to as the "**Purchaser**")

(individually referred to as "**Party**" and collectively as "**Parties**")

---

| | |
|:---|:---|
| **<u>RE:</u>** | **<u>SUPPLEMENTAL LETTER TO SECURITIES PURCHASE AGREEMENT DATED 22<sup>ND</sup> AUGUST 2024 AND FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT DATED 3<sup>RD</sup> OCTOBER 2024 ("Supplemental Letter")</u>** |

---

1. This Supplemental Letter sets forth the mutual agreement of the Parties of which the Parties hereby acknowledged, to be legally binding against them. Except otherwise expressly provided, all expressions defined in the Securities Purchase Agreement Dated 22<sup>nd</sup> August 2024 and First Amendment to Securities Purchase Agreement Dated 3<sup>rd</sup> October 2024 (collectively referred to as "**Private Placement SPAs**") and its supplemental agreement(s) shall have the same meanings when used in this Supplemental Letter.

2. The exercisable period for the Securities Purchase under *Section 2.1(a) and Section 2.1(b)* of the Private Placement SPAs shall be extended from <u>December 31, 2025</u> to <u>December 31, 2026</u>.

3. The purchase increments exercisable for the Securities Purchase under *Section 2.1(c)* of the Private Placement SPAs shall be reduced from tranche of ' <u>USD1million or USD2 million</u> ' to ' <u>USD500,000.00</u> '.

4. All other terms and conditions of the Private Placement SPAs and its supplemental agreement(s) shall remain the same. This Supplemental Letter shall go into effect on the date of the undersigned parties.

I/We confirm acceptance of the terms and conditions of this Supplemental Letter.

---

| | |
|:---|:---|
| **<u>The Company</u>** | **<u>The Purchaser</u>** |
| Signed for and on behalf of | Signed for and on behalf of |
| OpGen, Inc. | AEI Capital Ltd. |
|  | (Registration No. 970490-V) |
| ![](ex10-1_001.jpg) | ![](ex10-1_002.jpg) |

---